Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Study Number

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Full Title

A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma

ClinicalTrials.Gov ID

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail